Recent evidence has shown that members of the Jak kinase family are activated after IL-6 binds to its receptor complex, leading to a tyrosine phosphorylation of gpl30, the IL-6 signal-transducing subunit. The different members of the IL-6 cytokine subfamily induce distinct patterns of Jak-Tyk phosphorylation in different cell types. Using monospecific antibodies to gp130, Jak2 kinase, and phosphotyrosine, we investigated the kinetics of IL-6 stimulation of members of this pathway in primary hepatocytes. Our findings show that Jak 2 is maximally activated within 2 min of exposure to IL-6, followed by gpl30 phosphorylation that reaches its peak in another 2 min then declines to basal level by 60 min. In vitro phosphorylation experiments show that activated Jak 2 is able to phosphorylate both native gp130 and a fusion peptide containing its cytoplasmic domain, demonstrating gp130 is a direct substrate of Jak 2 kinase. Experiments designed to explore the cell surface expression of gp130 show that >2 h are required to get a second round of phosphorylation after the addition of more cytokines. This finding suggests that activated gpl30 is internalized from the cell surface after IL-6 stimulation. Additional experiments using protein synthesis inhibitors reveal that new protein synthesis is required to get a second cycle of gpl30 phosphorylation indicating gpl30 must be synthesized de novo and inserted into the membrane. These findings provide strong evidence that down regulation of the IL-6 signal in hepatocytes involves the internalization and cytosol degradation of gpl30.
INTRODUCTION
The interleukin-6 (IL-6) signal transducing protein, gpl30, has recently been shown to be a shared receptor subunit for at least four other cytokines, leukemia inhibitory factor, oncostatin M, ciliary neurotrophic factor (CNTF), and IL-11 (Bazan, 1991; Gearing et al., 1992; Ip et al., 1992; Stahl et al., 1993) . The members of the IL-6 cytokine subfamily that use gpl30 are able to stimulate the expression of some of the same genes (Rose and Bruce, 1991; Baumann et al., 1993) . Through specific binding receptors and a shared signal-transducing subunit (gp130), both redundancy and pleiotrophy are functional characteristics of members of this cytokine family (Lord et al., 1991; Kishimoto et al., 1992; . There are instances, however, in which cellular responses to different cytokines of the family differ quantitatively, implying at least a "preferred" cytokine for a specific cell response (Thoma et al., 1994) . For example, IL-6 is a more potent inducer of fibrinogen expression than LIF or IL-11 even though the latter cytokines do upregulate fibrinogen production (Baumann and Schendel, 1991; Lord et al., 1991) . These observations suggest that specificity of responses likely resides in subtle differences of components that participate in the intracellular pathway.
It has been postulated for several years that the common signal transducing subunit gpl30 should be a substrate for an intracellular kinase because it does not possess any intrinsic kinase activity itself (Hibi et al., 1990; Saito et al., 1992; Wang et al., 1992) . Thus an intensive search has been carried out to identify the intracellular kinases that phosphorylate gpl30. Within the past year results have been reported in which the Jak kinase family, consisting of three members, Jakl, Jak2, and Tyk2 (Wilks, 1989; Firmbach-Kraft et al., 1990; Wilks et al., 1991) , has been shown to be involved in the signaling process of IL-3 , erythropoietin , interferon a, y (Velazquez et al., 1992; Muller et al., 1993; Watling et al., 1993) , and growth hormone (Argetsinger et al., 1993) . It has been documented that different Jak kinases are activated by each member of the IL-6 cytokine family (Lutticken et al., 1994; Stahl et al., 1994) , and it also appears that the same cytokine activates a distinct pattern of Jak kinases in different cell types Watling et al., 1993; Stahl et al., 1994) . The activation of Jak2 kinase has not been investigated in hepatocytes nor has the direct phosphorylation of gp130 by Jak kinases been shown. In present study we used specific antibodies to elucidate in detail the activation of Jak2 kinase and gp130 phosphorylation in primary hepatocytes. Additional experiments using endogenous or recombinant gpl30 as a substrate in kinase assays demonstrate that gp130 molecule is directly phosphorylated by Jak2 kinase. Furthermore, our studies reveal that the time course of gpl30 phosphorylation disappearance is 1 h. Experiments were performed to determine whether gpl30 could be restimulated using a different cytokine (CNTF) and its cognate receptor (Davis et al., 1991; Ip et al., 1993) . The gp130 molecule cannot be rephosphorylated by the addition of either IL-6 or CNTF, suggesting that gp130 has been removed from the cell surface and made unavailable for further activation. Experiments utilizing protein synthesis inhibitors (cycloheximide and puromycin) show that protein synthesis is required for a second round of IL-6 signaling, implying that the activated gpl30 molecules are internalized and then degraded.
MATERIALS AND METHODS Materials
Tissue culture media, antibiotics and fetal bovine serum were purchased from GIBCO BRL (Gaithersburg, MD) and Hyclone (Logan, UT), respectively. The glutathione-S-transferase (GST) fusion protein expression and purification system was from Pharmacia (Piscataway, NJ). Restriction . Cells (1 X 107) were plated on 100 mm tissue culture plates and cultured in William's E media (minus arginine) for 18-24 h before the stimulation of cells.
Expression and Purification of gpl30 Fusion Protein
Two primers were designed according to the sequence of rat hepatic gpl30 in the cytoplasmic region between residues 645 and 918 (Wang et al., 1992) . The forward primer 5'-TTGGATCCGGAGGCCTAA-TTAAAAAACACATC-3' and reverse primer 5'-CCCTCTAGATCA-CTGTGGCATGTAGCC-3' were used to amplify the complete cytoplasmic domain by polymerase chain reaction using the full length gpl30 cDNA as a template. The amplified fragment was cloned into GST fusion protein expression vector pGEX-2T (Pharmacia). The designed 5' primer contains two additional glycine codons at the boundary between the GST and gpl3O fusion-protein. These additional glycine residues allow for more efficient thrombin cleavage.
For expression and purification of the gpl3O-GST fusion protein, the DH5a Escherichia coli strain transformed with pGEX-2T-gpl3O was cultured overnight in LB medium containing 100 Ag/ml ampicillin.
The overnight culture was then diluted 10-fold with fresh LB medium and incubated for 60 min, followed by the addition of 0.5 mM isopropyl-,B-D-thiogalactopyranoside, after which the induction proceeded for 5 h. The bacteria were collected by centrifugation and resuspend in ice-cold phosphate-buffered saline (PBS), containing 1 mM phenylmethylsulfonyl fluoride (PMSF). After sonication of 4 X 10 s, the cell lysate was adjusted to 1% Triton X-100 by adding 10% stock solution and then centrifuged (10 000 X g) for 10 min at 4°C to remove insoluble materials and intact cells The supernatant was applied to glutathione-sepharose affinity column (Pharmacia), and the bound fusion protein was eluted with 5 mM reduced glutathione in 50 mM tris(hydroxymethyl) aminomethane (Tris)-HCl, pH 8.0. To remove the GST portion from the fusion protein (GST-gpl30), the sample was digested with 0.1% human thrombin and loaded onto a glutathione-sepharose column (Ausubel et al., 1989) . The flow-through fraction contained gpl3O protein. The purified gpl30 protein was either used to immunize rabbit or as a substrate in Jak2 kinase activity assay.
Cytokines and Antibodies
Recombinant murine IL-6 was expressed and purified as previously documented (Grenett et al., 1991) . Murine CNTF was a generous gift from Dr. Rick Scott (Cephalon, West Chester, PA). Polyclonal antibodies against gpl3O were prepared by immunizing a rabbit with purified rat gpl3O cytoplasmic peptide. Briefly, 200 ug of gpl3O was mixed with equal volume of Freund's complete adjuvant and injected intradermally into 10-12 sites along the upper back of the rabbit. After 3 wk, 100 ,ig antigen and Freund's incomplete adjuvant mixture was injected subcutaneously into two to four additional sites. The antiserum titer was tested on day 31 by Western blot. The animal was boosted by an intramuscular injection of 100 ,ug of gpl30 protein then rested for an additional week before bleeding. High affinity antibodies to gpl30 cytoplasmic domain were partially purified by passing the serum over a protein A-sepharose resin (Ey et al., 1978) . The antisera against Jakl and Jak2 have been described and were provided as a generous gift from Dr. James Ihle (St. Judes Research Hospital, Memphis, TN). Anti-phosphotyrosine antibody (4G10) was purchased from UBI (Lake Placid, NY). Immunoprecipitated complexes were washed twice with 20 mM N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid (HEPES) (pH 7.4) and then resuspended in 50 ml of kinase buffer (10 mM HEPES pH 7.4, 50 mM NaCl, 5 mM MgCl2, 5 mM MnCl2). ['y-32p] ATP was added to yield a final concentration of 1 mCi/ml (Amersham). After incubation for 10 min at 30°C, the reaction was stopped with the addition of 10 mM EDTA. The samples were boiled in SDS sample buffer, resolved by SDS-PAGE, and visualized by autoradiography.
Immunoprecipitation and Western Blot Analysis
In the experiments of gpl3O phosphorylation [y_-32p] ATP was substituted by nonradioactive ATP, and immunoprecipitated native gpl30 or purified recombinant gpl3O protein was also added to kinase reaction as substrate. Then the tyrosine-phosphorylated proteins were detected by anti-pTyr blot using the ECL system.
RESULTS
Jak2 and gpl30 Are Rapidly Tyrosine Phosphorylated by IL-6 Stimulation in Hepatocytes Recent reports have shown that individual cytokines of the IL-6 family stimulate distinct patterns of Jak-Tyk phosphorylation in different cell lines (Stahl et al., 1994) . We therefore specifically examined Jak2 kinase activation by IL-6 in rat primary hepatocytes. Solubilized cellular proteins from IL-6-treated rat hepatocytes were immunoprecipitated using antibodies to gp130 or Jak2 and analyzed by anti-phosphotyrosine antibody (4G10) immunoblot. As shown in Figure 1 , IL-6 stimulates gp130 phosphorylation in a time-dependent manner. The phosphorylation of gp130 was evident at 2 min, reached the maximum level at 5 min, then became undetectable at 60 min. The time course for Jak2 phosphorylation presented in Figure 2A showed that it attained a peak value between 2 and 5 min. When the same filter was stripped and reprobed with anti-Jak2 antibody, the recognition of the p130 band by this antibody confirmed that it was Jak2 protein and moreover that each lane had been loaded with an comparable amount of protein ( Figure 2B ). Comparison of the first appearance of phosphorylation of gp130 and Jak2 revealed a subtle but reproducible lag time between Jak2 and gp130, demonstrating phosphorylation of Jak2 kinase precedes that of gp130. Experiments using various concentration of IL-6 also showed that the phosphorylation of gp130 and Jak2 occurred at physiological concentration of IL-6 as low as 5.0 ng/ml (-24 pM). IL-6 Activates Jak2 Kinase In Vitro Tyrosine phosphorylation of proteins is commonly associated with the activation of kinase activity (Hanks et al., 1988) . However the Jak2 phosphorylation stimulated by IL-6 does not necessarily prove that IL-6 activates Jak2 kinase, because it is possible that another intermediate kinase may be activated by IL-6 and then phosphorylates Jak2 protein. To confirm that IL-6 activates Jak2 kinase directly, we examined the in vitro activity of Jak2 kinase in IL-6-treated primary hepatocytes. After cells were stimulated with IL-6 for the times indicated, cell lysates were prepared and immunoprecipitated using anti-Jak2 serum. The immunoprecipitated proteins were added to an in vitro kinase assay system in the presence of [y-32P] ATP. The 32P-labeled proteins were resolved by SDS-PAGE, transferred to a nitrocellulose filter, and visualized by autoradiography ( Figure 3A) . Immunoprecipitates of extracts with antiJak2 serum from IL-6-stimulated cells showed strong kinase activity. In contrast, immunoprecipitates of extracts with normal rabbit serum had no detectable kinase activity. The maximum phosphorylation of Jak2 (or kinase activity) was observed in the cell extracts stimulated by IL-6 for 5 min. This dominant phosphoprotein was also detected when this same filter was blotted with 4G10 antibody, indicating the phosphorylation resided in tyrosine residues ( Figure 3B ). These data show that IL-6 stimulates tyrosine kinase activity of Jak2 that also induces autophosphorylation of Jak2.
Both Native and Recombinant gpl30 Protein Are Tyrosine Phosphorylated by Activated Jak2 Kinase Jak kinases are associated with gp130 in several cell types (Lutticken et al., 1994; Stahl et al., 1994) . Data presented in this study also show that IL-6 activates Jak2 kinase (Figure 3) . Furthermore, the appearance of gp130 phosphorylation corresponds in time with Jak2 activation suggesting that gpl30 is a substrate for Jak2
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Reprobed with anti-Jak 2 Figure 2 . IL-6 induces Jak2 phosphorylation. Cells were stimulated as described in Figure 1 Figure 4A ). The findings revealed that the endogenous gpl30 proteins from unstimulated cells were phosphorylated by the IL-6-activated Jak2 kinase. The tyrosine-phosphorylated gpl30 proteins were only detected in the extracts of IL-6-stimulated cells that immunoprecipitated with anti-Jak2, not in normal rabbit serum immunoprecipitation of either stimulated or unstimulated cells ( Figure  4A , lanes 6 and 7). To demonstrate convincingly that Jak2 kinase, not a contaminating tyrosine kinase in the anti-Jak2 immunoprecipitate, directly phosphorylates gpl30, we performed the following experiment. Both unstimulated and IL-6-treated cells were immunoprecipitated with anti-Jak2 and preimmune serum under conditions identical to those employed above, and a anti-phosphotyrosine antibody (4G 10) was used to detect tyrosine kinases present in the immunoprecipitate. As shown in Figure 5A , only one tyrosine-phosphorylated band, which migrated to 130 kDa position, was visualized. When the same filter was reprobed with anti-Jak2, the identity of Jak2 kinase was confirmed. Moreover, gp130
was not co-immunoprecipitated with anti-Jak2 nor Jak2 with anti-gpl30 in the NP-40 lysis buffer we used (Figure 6B ). This is consistent with the studies carried out by others (Lutticken et al., 1994; Stahl et al., 1994) Anti-Jak2 endogenous gpl30. As an extension of these findings, a fusion protein containing the cytoplasmic domain of gpl3O was used as the substrate for the activated Jak2
kinase. The results shown in Figure 6A indicate that the gpl3O fusion protein could also serve as a substrate for the Jak2 kinase. The results of these two experiments provide direct experimental data that gp130 is a specific substrate of Jak 2 and further demonstrate that IL-6 stimulates Jak 2 kinase in primary hepatocytes. It should be noted that IL-6 also activated Jakl kinase and then caused the phosphorylation of gpl3O in primary hepatocytes (unpublished results). This latter observation implies that both kinases are stimulated by IL-6 in the hepatocyte and likely cooperate in the phosphorylation of gp130.
Genistein Inhibits Jak 2 Kinase Activity and Phosphorylation of gpl30 If Jak2 kinase phosphorylates gpl30, the inhibition of Jak2 kinase activity should also cause a decrease of gpl30 phosphorylation. We utilized a highly specific tyrosine kinase inhibitor, genistein (Akiyama et al., 1987) , to explore further the Jak2 kinase activity and gpl3O phosphorylation. The primary hepatocytes were incubated with fresh media in the absence or presence of genistein for 30 min. Then cells were stimulated by IL-6 (100 ng/ml) for 5 min, and the extracts of cell lysates were applied to immunoprecipitation with indicated antibodies (ak2, gp13O, and normal rabbit serum control). The phosphorylated proteins were then detected by anti-phosphotyrosine immunoblot ( Figure  7 ). It was shown that genistein blocked the phosphorylation of Jak2 kinase and subsequently caused a significant decrease of gp130 phosphorylation (lanes 9 and Figure 6 . (Stahl et al., 1994) . The experimental results here support the idea that Jak2 kinase directly phosphorylates gp130 protein in IL-6 signaling pathway in hepatocytes.
The gpl30 Is Internalized After IL-6 Stimulation
A common mechanism that cells employ to modulate a stimulatory signal is to endocytose the ligand-receptor complex thereby making receptors unavailable for signaling (Carpenter and Cohen, 1976; Mellman et al., 1986; Tran et al., 1987 (lanes 1-10) , cells were stimulated by rmIL-6 (100 ng/ml) for the indicated times. In the bottom panel, cells were first stimulated with IL-6 for 1 h, followed by addition of fresh cytokine (IL-6, lanes 11-15; or CNTF, lanes 16-20) for different time periods. Cells were immediately lysed for immunoprecipitation using anti-gpl30. The phosphorylated gpl30 was detected by 4G10 immunoblot.
the ligand is processed to the lysosome for degradation (Goldstein et al., 1985; Marshall, 1985) . Another possible route for the receptor to follow is after intemalization both the ligand and receptor remain together and are processed to the lysosome for degradation (Brown and Greene, 1991; Sorkin and Waters, 1993; Straight et al., 1993) . We have previously reported that 125-iodinelabeled IL-6 is rapidly intemalized and degraded (Nesbitt and Fuller, 1992b), however, in those studies we were unable to determine if this internalization also included the gpl30 subunit.
Experiments were carried out here to determine the time course of activation and reactivation of gpl30 (Figure 8 Figure 8 (lanes 11-15) demonstrate that the addition of more IL-6 had no effect in initiating gpl30 phosphorylation. The possibility exists that the IL-6 cognate receptor (gp8O) could be a limiting factor so that reactivation of gpl30 is not possible. Because CNTF binds to its own receptor before association with gpl30 (Ip et al., 1992) and stimulates an acute phase response in liver cells, we used this cytokine to determine if a second gpl30 phosphorylation could be generated after an initial IL-6 activation. As shown in Figure 8 (lanes [16] [17] [18] [19] [20] , CNTF also failed to generate a second wave of gpl30 phosphorylation indicating that gp130 was the limiting subunit in this reactivation process.
To determine the length of time that the cell required to be able to respond to a second IL-6 signal, we pulsed the cells with IL-6 after the initial signaling event had occurred. Cells were first treated with IL-6 for 1 h, then fresh media containing no cytokine was added. At the end of 1, 2, and 4 h, the cells were restimulated by adding IL-6 for 5 min before processing for gpl30 phosphorylation (Figure 9 ). The results show that a small amount of gpl30 activation could be detected at 1 h but had returned to nearly full responsiveness by 4 h. On the other hand, the gp130 phosphorylation signal in the continual presence of IL-6 was somewhat higher than background but no pronounced phosphorylation was detected (Figure 8, lanes 3-10) . These findings together predict that the gp130 molecule is removed from cell surface and internalized with the bound ligand in the IL-6 signal process.
Protein Synthesis Is Required for gpl30 Reentry to Signal Pathway Two possible explanations could account for the fate of internalized gpl30 molecules. First, it is possible that activated gpl30 is internalized and, following separation from the ligand, could recycle to the cell surface. Second, gp130 could be targeted for degradation, and new gpl30 has to be synthesized before it appears in the membrane. To determine if protein synthesis is required for the gpl30 reentry to the signaling pathway, we used two well-defined protein synthesis inhibitors cycloheximide (CHX) and puromycin (PUR). It is conceivable that transcription may be essential for the cell to reset the gpl30 signal, therefore we also used the transcriptional inhibitor, actinomyocin-D (ACT-D). Hepatocytes were stimulated with IL-6 for 1 h to remove the cell surface protein of gpl30, after which fresh media was added in the presence of indicated inhibitors and incubated for an additional 4 h. Cells were then restimulated by adding IL-6. Phosphorylation of gp130 was observed both in noninhibitor-treated cells and cells treated with actinomycin D. In contrast, gpl30 phosphorylation could not be detected in cells treated with either of the protein synthesis inhibitors ( Figure 10A ). As a control, cells were treated with CHX, PUR, and ACT-D for 4 h then stimulated with IL-6. These inhibitors had no effect on the capacity of IL-6 to activate gpl30 molecules that had already been expressed on the cell surface ( Figure   10B ). The disappearance of gpl30 initiated by IL-6 1 2 3 4 5 6 7 8 Figure 9 . Accumulation and activation of cell surface gp130. binding was also detected directly by anti-gp130 blot. Cells were treated as previously described and lysed for immunoprecipitation and blot with a monospecific antibody to gpl30 protein (Figure 1 A) . The diminution of gpl30 was detected in the presence of protein synthesis inhibitors (CHX and PUR) that prevented the reappearance of newly synthesized gpl30. These inhibitors had not effect on gpl30 detection if the cells were not stimulated by IL-6 (Figure 1lB ). Taken together, these findings provide evidence that gpl30 is internalized and degraded after IL-6 stimulation and that new gpl30 must be synthesized, processed, and inserted into the membrane before additional signals can be generated. DISCUSSION IL-6 is the major signaling cytokine for the liver during an acute inflammatory response. The currently accepted paradigm for this signal process is that IL-6 first binds to a cognate receptor (gp8O) at a relatively low affinity, and then this complex associates with a second transmembrane subunit (gpl30) forming a high-affinity ligand receptor complex (Taga et al., 1989; Hibi et al., 1990) . It is now believed that the first event in second phase of this association is to initiate dimerization of the gp130 subunits. The dimer is then stabilized through an interchain disulfide linkage between two gp130 molecules (Murakami et al., 1993) . The third event that has been measured is the phosphorylation of gp130 resulting in a conformational change that is involved in relaying the IL-6 signal (Murakami et al., 1991) . Because gp130 itself is not a kinase, the last event must include the activation of yet another molecule. Recently it has been shown that a family of cytoplasmic kinases known as the Jak kinase family is involved in the IL-6 signal pathway (Lutticken et al., 1994; Stahl et al., 1994 (Lutticken et al., 1994; Stahl et al., 1994) , the direct linkage between them is not completely understood. It is important to understand the step-by-step details of this pathway. Therefore, we examined the time course of Jak2 and gpl30 activation and demonstrated that there is a subtle but detectable difference in the appearance of phosphorylation of each of the two proteins, suggesting that the Jak2 kinase may be "activated" first by ligand-induced homodimerization of gpl30 and become autophosphorylated. Our finding that Jak2 kinase is phosphorylated and activated by IL-6 stimulation in primary hepatocytes also extended findings of the previous study that Jakl and Tyk2 kinases are activated in HepG2 cells (Lutticken et al., 1994) . Because Jak family kinases are intimately associated with the cytoplasmic domain of gpl30 constitutively but only activated by ligand binding (Stahl et al., 1994) , the process of dimerization of gp130 is likely the critical physical rearrangement that stimulates Jak2 phosphorylation by as yet an unknown mechanism.
We also reported here that either endogenous gpl30 from unstimulated cells or purified recombinant gp130 fusion protein were directly phosphorylated by IL-6-activated Jak2 kinase. When Jak2 kinase activity was blocked by a tyrosine kinase inhibitor (genistein), the phosphorylation of gp130 protein was also inhibited. These data together indicated that gp130 is the first identified substrate for the Jak kinase family. Other potential candidate substrates for Jak kinases may include transcription factors, p91, a member of the interferon- Figure 11 . Detection of gp130 degradation after IL-6 stimulation. Cells were treated as described in Figure 10 . After anti-gpl3O immunoprecipitation, the pellets were fractionated by SDS-PAGE and blotted with an antibody to rat hepatic gp130.
a and -'y signaling pathway Decker et al., 1991; Schindler et al., 1992; Shuai et al., 1992) , and the acute phase response factor protein (Wegenka et al., 1993) . It is important to point out that both Jakl and Tyk2 kinases are activated by IL-6 family cytokines in hepatoma cell line (Lutticken et al., 1994) . Additional experiments carried out in our laboratory showed that IL-6 activates Jakl kinase and as effectively phosphorylates gpl3O as Jak2 in primary hepatocytes. This latter observation implies that both kinases are stimulated by (Fujii et al., 1986; Quarnstrom et al., 1988; Galizzi et al., 1989; Sorkin et al., 1991; Sorkin and Waters, 1993) . Some hint that this pathway may be the likely mechanism for gpl3O was shown when we reported that IL-6 was internalized and degraded (Nesbitt and Fuller, 1992b) . The first clue to the possibility that the downregulation pathway used by gpl30 involved internalization came from the reactivation experiments. After the initial gpl30 phosphorylation occurred after IL-6 exposure for 1 h, which it is enough to endocytose 90% of bound ligand from the cell surface (Nesbitt and Fuller, 1992b) , the addition of more IL-6 did not produce a second round phosphorylation of gpl30. Because CNTF also uses gpl30 as a signal transducing subunit and its own specific receptor for ligand binding, we added CNTF to the already IL-6-stimulated cells to determine the availability of surface expressed gpl30. The finding that no additional phosphorylation occurred indicated that gpl30 was not available for activation. To determine the length of time required to get a second phosphorylation event, experiments were performed in which the cells were "rested", i.e., IL-6 was removed and then at different times IL-6 again added to the cells. Phosphorylation could be detected after 1 h but was nearly fully restored by 4 h. On the other hand cells that were in the presence of IL-6 continuously after the initial signal did not give a strong second response at the end of 2 h post stimulation. We do note, however, a higher base-line of phosphorylation suggesting that when gpl30 was again made available it was quickly phosphorylated and removed from the activation cycle. Taken together these data indicated that phosphorylated gpl30 was removed from cell surface and internalized. Additional experiments were carried out using protein synthesis inhibitors as a way to determine if gpl30 could return to the signaling cycle by a mechanism that did not involve new gpl30 protein synthesis. The results of these experiments showed that in the presence of protein synthesis inhibitors (cycloheximide and puromycin) no IL-6 signal occurred after the initial signal was made. Unlike the IL-4 receptor in which cell surface reexpression is prevented by both cycloheximide and actinomycin-D (Galizzi et al., 1989) , gpl30 reexpression is not affected by actinomycin-D within the time period examined (4 h). This finding is not unexpected in the view of the abundant mRNA level and long half life (12 h) of gp130 (Nesbitt and Fuller, 1992a; Saito et al., 1992; Wang et al., 1992) . Our results clearly indicate that gpl30 is likely degraded together with IL-6 and that the downregulation pathway is similar to that of other growth factors involving destruction of both the ligand and receptor.
In summary, the results of these experiments provide more detailed information about the IL-6 signal pathway in hepatocytes. Our data demonstrate clearly that the Jak kinases phosphorylate gp130 in this cell. Additionally, we provide the first information on the fate of gpl30 after its activation by showing that it is internalized and most likely degraded.
